Imaginostics is a health tech startup developing magnetic resonance imaging (MRI) technology, with locations in Boston and Baltimore. We are developing non-invasive diagnostic solutions for renal-safe vascular angiography and breakthrough quantitative imaging biomarkers that can provide new insight into health and disease. We have a nimble, innovative, and growing team that embraces a bold vision to take breakthroughs in magnetic resonance imaging and transform them into a platform that can improve lives.
Our proprietary QUTE-CE MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body at the single-patient level, providing scientific and clinical researchers new endpoints for early detection and enhanced characterization of complex diseases. Data can be used to visualize the vasculature, assay health and disease, stratify research populations, support early preventative diagnostics, and help assess drug efficacy. We also provide biomarker solutions commercially through CROs to pharma and participate in pre-clinical and clinical research in a variety of focus areas collaborating with world-renowned researchers at leading institutions. Our technology and software are compatible with existing MRI scanners.
Imaginostics’ research / development focus areas include:
• Safe Full Body Vascular Enhanced Imaging for Renally Impaired Groups
• Neurological Drug Characterization (Vascular Function, Density and Structure)
• Biomarkers for Alzheimer’s Disease and Related Dementias (ADRD)
• Traumatic Brain Injury (TBI)
• Cardiovascular Biomarkers
• Kidney Biomarkers
Please reach out if you would like to explore opportunities to work together:
• Pharmaceutical Companies
• Hospitals
• Academic Research Collaborators
• Investors
• Engineers and Researchers (please see current openings)
To learn more, please visit: http://www.imaginostics.com
Our proprietary QUTE-CE MRI methodology can non-invasively assay vascular structure, function, and leakage in high resolution anywhere in the body at the single-patient level, providing scientific and clinical researchers new endpoints for early detection and enhanced characterization of complex diseases. Data can be used to visualize the vasculature, assay health and disease, stratify research populations, support early preventative diagnostics, and help assess drug efficacy. We also provide biomarker solutions commercially through CROs to pharma and participate in pre-clinical and clinical research in a variety of focus areas collaborating with world-renowned researchers at leading institutions. Our technology and software are compatible with existing MRI scanners.
Imaginostics’ research / development focus areas include:
• Safe Full Body Vascular Enhanced Imaging for Renally Impaired Groups
• Neurological Drug Characterization (Vascular Function, Density and Structure)
• Biomarkers for Alzheimer’s Disease and Related Dementias (ADRD)
• Traumatic Brain Injury (TBI)
• Cardiovascular Biomarkers
• Kidney Biomarkers
Please reach out if you would like to explore opportunities to work together:
• Pharmaceutical Companies
• Hospitals
• Academic Research Collaborators
• Investors
• Engineers and Researchers (please see current openings)
To learn more, please visit: http://www.imaginostics.com
Location: United States, Massachusetts, Cambridge
Employees: 1-10
Total raised: $915.93K
Founded date: 2018
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.09.2022 | Grant | $915.93K | - |
Mentions in press and media 1
| Date | Title | Description |
| 14.01.2021 | GTT Group’s Patent Equity Fund Ideaship Invests in Imaginostics to Develop Non-Invasive Diagnostic Solutions | “Imaginostics has partnered with Ideaship to ensure the success of our early products and services via a strong IP portfolio. Our vascular imaging technology is ready to help millions of chronic kidney disease patients..." Said Codi Gh... |